Higher Sclerostin is Associated with Pulmonary Hypertension in Pre-dialysis End-stage Kidney Disease Patients: a Cross-sectional Prospective Observational Cohort Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Feb 10

PMID 38341544

Authors

Jonghyun Lee

Dong-Hyuk Cho

Hyeon-Jin Min

Young-Bin Son

Tae Bum Kim

Se Won Oh

Myung-Gyu Kim

Won Yong Cho

Sang-Kyung Jo

Jihyun Yang

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary hypertension (PH) is a complication of chronic kidney disease (CKD) that contributes to mortality. Sclerostin, a SOST gene product that reduces osteoblastic bone formation by inhibiting Wnt/β-catenin signaling, is involved in arterial stiffness and CKD-bone mineral disease, but scanty evidence to PH. This study explored the relationship between sclerostin and PH in CKD 5, pre-dialysis end-stage kidney disease (ESKD) patients.

Methods: This cross-sectional prospective observational cohort study included 44 pre-dialysis ESKD patients between May 2011 and May 2015. Circulating sclerostin levels were measured using an enzyme-linked immunosorbent assay. PH was defined as an estimated pulmonary artery systolic pressure > 35 mmHg on echocardiography.

Results: Patients with higher sclerostin levels ≥ 218.18pmol/L had echocardiographic structural cardiac abnormalities, especially PH (P < 0.01). On multivariate logistic analysis, sclerostin over 218.19pmol/L was significantly associated with PH (odds ratio [OR], 41.14; 95% confidence interval [CI], 4.53-373.89, P < 0.01), but multivariate Cox regression analysis showed the systemic vascular calcification score over 1 point (Hazard ratio [HR] 11.49 95% CI 2.48-53.14, P = 0.002) and PH ([HR] 5.47, 95% CI 1.30-23.06, P = 0.02) were risk factors for all-cause mortality in pre-dialysis ESKD patients.

Conclusions: Serum sclerostin and PH have a positive correlation in predialysis ESKD patients. The higher systemic vascular calcification score and PH have an association to increase all-cause mortality in pre-dialysis ESKD patients.

Citing Articles

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.

Chiu S, Wu W, Yao T, Peng C, Yeh K Biomedicines. 2025; 12(12.

PMID: 39767786 PMC: 11673789. DOI: 10.3390/biomedicines12122880.

Kidney transplantation in the presence of pulmonary hypertension: A clinical dilemma.

Farshbafnadi M, Ghannadzadeh Kermani Pour R, Sattarzadeh Badkoubeh R, Geraiely B, Mehrpooya M, Larti F Heliyon. 2024; 10(20):e39074.

PMID: 39640609 PMC: 11620137. DOI: 10.1016/j.heliyon.2024.e39074.

References

Navaneethan S, Roy J, Tao K, Brecklin C, Chen J, Deo R . Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol. 2015; 27(3):877-86. PMC: 4769189. DOI: 10.1681/ASN.2014111111. View

Faqih S, Noto-Kadou-Kaza B, Abouamrane L, Mtiou N, El Khayat S, Zamd M . Pulmonary hypertension: prevalence and risk factors. Int J Cardiol Heart Vasc. 2017; 11:87-89. PMC: 5462628. DOI: 10.1016/j.ijcha.2016.05.012. View

Zeng C, Guo C, Cai J, Tang C, Dong Z . Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diab Vasc Dis Res. 2017; 15(2):99-105. DOI: 10.1177/1479164117742316. View

Edmonston D, Parikh K, Rajagopal S, Shaw L, Abraham D, Grabner A . Pulmonary Hypertension Subtypes and Mortality in CKD. Am J Kidney Dis. 2019; 75(5):713-724. PMC: 7183902. DOI: 10.1053/j.ajkd.2019.08.027. View

Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A . Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2013; 99(1):248-55. DOI: 10.1210/jc.2013-2786. View

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(3):233-70. DOI: 10.1093/ehjci/jev014. View

Tang M, Batty J, Lin C, Fan X, Chan K, Kalim S . Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2018; 72(1):75-83. DOI: 10.1053/j.ajkd.2017.11.018. View

Carrillo-Lopez N, Panizo S, Alonso-Montes C, Martinez-Arias L, Avello N, Sosa P . High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Nephrol Dial Transplant. 2018; 34(6):934-941. DOI: 10.1093/ndt/gfy287. View

Nagueh S, Smiseth O, Appleton C, Byrd 3rd B, Dokainish H, Edvardsen T . Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016; 17(12):1321-1360. DOI: 10.1093/ehjci/jew082. View

10.

Krishna S, Seto S, Jose R, Li J, Morton S, Biros E . Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis. Arterioscler Thromb Vasc Biol. 2017; 37(3):553-566. DOI: 10.1161/ATVBAHA.116.308723. View

11.

de Oliveira R, Barreto F, Mendes M, Dos Reis L, Castro J, Britto Z . Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2014; 87(5):1039-45. DOI: 10.1038/ki.2014.372. View

12.

Modder U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B . Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2010; 26(2):373-9. PMC: 3179347. DOI: 10.1002/jbmr.217. View

13.

Zanoli L, Lentini P, Briet M, Castellino P, House A, London G . Arterial Stiffness in the Heart Disease of CKD. J Am Soc Nephrol. 2019; 30(6):918-928. PMC: 6551785. DOI: 10.1681/ASN.2019020117. View

14.

Kim S, Chang H, Kim M, Jo S, Cho W, Kim H . Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients. Kidney Res Clin Pract. 2015; 34(1):28-34. PMC: 4570633. DOI: 10.1016/j.krcp.2015.01.003. View

15.

Yang C, Chang Z, Chau Y, Chen A, Yang W, Yang A . Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015; 30(8):1356-63. DOI: 10.1093/ndt/gfv043. View

16.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

17.

Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M . A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004; 19(6):1480-8. DOI: 10.1093/ndt/gfh217. View

18.

Bhattacharya P, Abdul Hameed A, Bhattacharya S, Chirinos J, Hwang W, Birati E . Risk factors for 30-day readmission in adults hospitalized for pulmonary hypertension. Pulm Circ. 2020; 10(4):2045894020966889. PMC: 7686634. DOI: 10.1177/2045894020966889. View

19.

Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo J . Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2011; 97(1):234-41. DOI: 10.1210/jc.2011-2186. View

20.

De Mare A, Maudsley S, Azmi A, Hendrickx J, Opdebeeck B, Neven E . Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis. Toxins (Basel). 2019; 11(7). PMC: 6669501. DOI: 10.3390/toxins11070428. View